In one study, 7/38 (18%) of lung adenocarcinomas, 2/17 (12%) of lung squamous cell carcinomas, 4/10 (40%) of thymic carcinomas, 4/12 (33%) of adenoid cystic carcinomas, 1/19 (5%) of diffuse large B-cell lymphomas, 4/11 (36%) of alveolar rhabdomyosarcomas, and 4/23 (17%) of Ewing sarcomas were positive for INSM1. This evidence concerns the gene INSM1 and rhabdomyosarcoma.